These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 8751408)

  • 1. Abdomino-pelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: feasibility, tolerance and pharmacology.
    Formenti SC; Shrivastava PN; Sapozink M; Jozsef G; Chan KK; Jeffers S; Morrow PC; Muggia FM
    Int J Radiat Oncol Biol Phys; 1996 Jul; 35(5):993-1001. PubMed ID: 8751408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
    Los G; Smals OA; van Vugt MJ; van der Vlist M; den Engelse L; McVie JG; Pinedo HM
    Cancer Res; 1992 Mar; 52(5):1252-8. PubMed ID: 1737387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.
    Steller MA; Egorin MJ; Trimble EL; Bartlett DL; Zuhowski EG; Alexander HR; Dedrick RL
    Cancer Chemother Pharmacol; 1999; 43(2):106-14. PubMed ID: 9923815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-abdominal temperature distribution during consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of advanced stage ovarian carcinoma.
    Rettenmaier MA; Mendivil AA; Gray CM; Chapman AP; Stone MK; Tinnerman EJ; Goldstein BH
    Int J Hyperthermia; 2015 Jun; 31(4):396-402. PubMed ID: 25707816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer.
    Westermann AM; Grosen EA; Katschinski DM; Jäger D; Rietbroek R; Schink JC; Tiggelaar CL; Jäger E; Zum Vörde sive Vörding P; Neuman A; Knuth A; Van Dijk JD; Wiedemann GJ; Robins HI
    Eur J Cancer; 2001 Jun; 37(9):1111-7. PubMed ID: 11378341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma.
    Lentz SS; Miller BE; Kucera GL; Levine EA
    Gynecol Oncol; 2007 Jul; 106(1):207-10. PubMed ID: 17498782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study.
    Argenta PA; Sueblinvong T; Geller MA; Jonson AL; Downs LS; Carson LF; Ivy JJ; Judson PL
    Gynecol Oncol; 2013 Apr; 129(1):81-5. PubMed ID: 23352917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole body hyperthermia and intraperitoneal carboplatin in residual ovarian cancer.
    Cohen JD; Robins HI
    Adv Exp Med Biol; 1990; 267():197-202. PubMed ID: 2088035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
    Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
    Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer.
    Hager ED; Dziambor H; Höhmann D; Mühe N; Strama H
    Int J Gynecol Cancer; 2001; 11 Suppl 1():57-63. PubMed ID: 11489005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
    Miyagi Y; Fujiwara K; Kigawa J; Itamochi H; Nagao S; Aotani E; Terakawa N; Kohno I;
    Gynecol Oncol; 2005 Dec; 99(3):591-6. PubMed ID: 16095677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
    Cascales-Campos PA; Gil J; Feliciangeli E; Gil E; González-Gil A; López V; Ruiz-Pardo J; Nieto A; Parrilla JJ; Parrilla P
    Ann Surg Oncol; 2015 Mar; 22(3):987-93. PubMed ID: 25212832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
    Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E
    Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.
    van de Vaart PJ; van der Vange N; Zoetmulder FA; van Goethem AR; van Tellingen O; ten Bokkel Huinink WW; Beijnen JH; Bartelink H; Begg AC
    Eur J Cancer; 1998 Jan; 34(1):148-54. PubMed ID: 9624250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study.
    Kapp KS; Kapp DS; Stuecklschweiger G; Berger A; Geyer E
    Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):189-99. PubMed ID: 8270441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience.
    Mendivil AA; Rettenmaier MA; Abaid LN; Brown JV; Mori KM; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):405-410. PubMed ID: 28669065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The retreatment of carboplatin via high-dose intraperitoneal chemotherapy in patients with a history of a hypersensitivity reaction.
    Rettenmaier MA; Gray CM; Lopez KL; Bechtol KA; Goldstein BH
    Am J Obstet Gynecol; 2014 Feb; 210(2):e1-2. PubMed ID: 24184183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial.
    Deraco M; Kusamura S; Virzì S; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Iusco DR; Baratti D
    Gynecol Oncol; 2011 Aug; 122(2):215-20. PubMed ID: 21665254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer.
    Douwes F; BogoviC J; Douwes O; Migeod F; Grote C
    Int J Clin Oncol; 2004 Apr; 9(2):85-91. PubMed ID: 15108039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer.
    Nagao S; Fujiwara K; Ohishi R; Nakanishi Y; Iwasa N; Shimizu M; Goto T; Shimoya K
    Int J Gynecol Cancer; 2008; 18(6):1210-4. PubMed ID: 18284454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.